Clinical Trials Logo

Clinical Trial Summary

This is a prospective natural history study on patients with clinically defined sIBM. Participants will be assessed every 6 months over two years (five visits total). We will include 150 participants, enrolled across 13 sites, with sporadic IBM, diagnosed according to established criteria.


Clinical Trial Description

This is a prospective natural history study on patients with clinically defined sIBM. Participants will be assessed every 6 months over two years (five visits total). We will include 150 participants with sporadic IBM, diagnosed according to established criteria. Participants will require an routine serum sample via blood draw to evaluate for NT5c1A antibody status. This testing will be performed at Washington University School of Medicine in the Neuromuscular Laboratory. Investigators will be blinded to antibody status. A subset of participants (40) will undergo a muscle biopsy at the Baseline visit. Aim 1. To determine for the first time whether NT5c1A antibodies mediate disease progression over a two-year interval in patients with sIBM. We will perform a prospective, non-interventional, observational study on patients with sIBM with follow up and evaluations every 6 months over a two-year time frame. Primary analyses are: 1) the rates of disease progression and severity as measured by rates of decline in IBM Functional Rating Scale (IBMFRS) score and Timed Get Up and Go (TUG); 2) the presence or absence of serum antibodies to NT5c1A; and 3) the presence and frequency of variant T-cells in the serum and skeletal muscle. Aim 2. To perform a detailed morphological, histochemical and immunohistochemical analysis of fresh muscle biopsy specimens obtained from a subset of patients with sIBM. Aim 3. To characterize the distribution of "immunosenescent" lymphocytes in circulating blood from patients with sIBM. Aim 4. To quantify the decline in the respiratory function of sIBM patients. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05046821
Study type Observational
Source University of California, Irvine
Contact
Status Active, not recruiting
Phase
Start date October 11, 2021
Completion date January 31, 2026

See also
  Status Clinical Trial Phase
Completed NCT00769860 - Arimoclomol in Sporadic Inclusion Body Myositis Phase 2/Phase 3
Completed NCT01165008 - Anakinra in Myositis Phase 2/Phase 3
Recruiting NCT05890833 - The Risk of Falls Index for Patients With Neuromuscular Disorders
Recruiting NCT06153108 - Monitoring Biomarker for Detecting Change in Physical Activity and Limb Function in Inclusion Body Myositis Over Time
Active, not recruiting NCT04659031 - A Phase 1 Study of ABC008 in Ascending (Single Ascending Dose/Multiple Ascending Dose) Study in Patients With (IBM) Phase 1
Completed NCT03440034 - Study of Pioglitazone in Sporadic Inclusion Body Myositis Phase 1
Terminated NCT04049097 - Arimoclomol in Sporadic Inclusion Body Myositis - Open Label Extension Trial Phase 3
Completed NCT00001261 - Intravenousimmunoglobulin (IVIg) for the Treatment of Inflammatory Myopathies Phase 2
Recruiting NCT05272969 - Pompe & Pain - Study to Assess Nociceptive Pain in Adult Patients With Pompe Disease
Completed NCT01734369 - Environmental Risk Factors for Myositis in Military Personnel
Active, not recruiting NCT04975841 - Inclusion Body Myositis Treatment With Celution Processed Adipose Derived Regenerative Cells N/A
Recruiting NCT00017914 - Adult and Juvenile Myositis
Completed NCT00917956 - Lithium in Inclusion Body Myositis (IBM) N/A
Completed NCT03633318 - Establishing Muscle Impedance Parameters With Electrical Impedance Myography
Recruiting NCT04789070 - Phase III Trial of Sirolimus in IBM Phase 3
Active, not recruiting NCT05721573 - A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis Phase 2/Phase 3
Recruiting NCT05032131 - Cell Therapy for IBM by Muscle Injection of ADSVF Phase 1
Completed NCT03299335 - Molecular Profile of the Evolution of Inclusion Body Myositis N/A
Completed NCT04421677 - Safety and Tolerability of Phenylbutyrate in Inclusion Body Myositis Phase 1
Completed NCT02753530 - Study of Arimoclomol in Inclusion Body Myositis (IBM) Phase 2